ReviewMedicine2026
Medication patterns and therapeutic strategies in Traditional Chinese Medicine for coronary heart disease: A text mining analysis of clinical literature.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of coronary heart disease (CHD) has increased. This study employed scientific statistical methods to explore the medication rules of Chinese herbal medicines (CHMs) to treat CHD and provide a scientific and reliable theoretical basis for the improvement of patient symptoms. We systematically retrieved relevant studies related to CHMs used to treat CHD from the VIP, CNKI, Wanfang. We used Microsoft Excel 2019 to establish a database and the Ancient and Modern Medical Case Cloud Platform to conduct frequency, association rule, cluster analyses and complex network analysis. Summarize the prescribed medication rules of Chinese medicine for the internal treatment of CHD and visualize the graphic representation. We obtained 144 papers with 362 experimental cases and 149 herbs based on the screening criteria. These records, which include the medical expertise of well-known provincial and local Traditional Chinese Medicine practitioners spanning over 2 decades, hold significant value in directing the clinical use of medications and the creation of novel drugs. The three most frequently used herbs were Radix et Rhizoma Salviae Miltiorrhizae (Danshen), Rhizoma Chuanxiong (Chuanxiong), and Radix Astragali (Huangqi). Fifteen of the 20 flavors of high-frequency herbs appear in the Shen Nong's Classic of the Materia Medica (Shén Nóng Bĕn Căo Jīng). These medications are crucial for the flow of Qi and the management of a number of cardiac disorders. The properties and taste of herbs were mainly warm and sweet, respectively. We obtained 25 association rules and 5 new clusters. The Chuanxiong Rhizoma (Chuanxiong) and Radix et Rhizoma Salviae Miltiorrhizae (Danshen) herb pair had the strongest correlation. We found that famous Chinese medicine practitioners who have been treating CHD for many years utilize Blood-invigorating and supplementing medicines. At the same time, they collaborated with Bulbus Allii Macrostemi (Xiebai) and Ramulus Cinnamomi (Guizhi) to diffuse Bì and unblock Yang. The Buyang Huanwu Decoction (BYHWD) and Shengmai San (SMS) were the primary CHM prescription for CHD. In addition, we further verified the experience of not using Radix Paeoniae Alba (Baishao) for chest oppression, not using Rhizoma Pinelliae (Banxia) for dry mouth, and not using Rhizoma Atractylodis Macrocephalae (Baizhu) for constipation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.